Institute of Biomedical Technologies

Personalization of cancer treatments

Principal Investigator

Fernando Gutiérrez Nicolás, PhD

Head of Research Unit, Specialist Physician in Hospital Pharmacy Area CHUC

 

Collaborating researchers

  • Ruth Ramos Díaz, PhD (Molecular Biologist, Head of the Genetics Section, Research Unit, CHUC)
  • María Micaela Viña, PhD (Hospital Pharmacist in the Onco-Hematology area, Head of the Hematology Section, Research Unit, CHUNSC)
  • Sara García, PhD (Hospital Pharmacist in the Onco-Hematology area, Head of the Immune-Mediated and Statistical Development Section, CHUC)
  • Ivette Mourani (Molecular Biologist, Head of Chromatography Area and Data Manager)
  • Juana Oramas, PhD (Head of the Medical Oncology Service, CHUC – Support to the Oncology Area)
  • Matías Llabrés, PhD (Professor of Pharmaceutical Technology, ULL – development of clinical models)

PhD students and researchers in training

  • Betel del Rosario, PhD (Doctoral Program in Health Sciences, ULL. Hospital Pharmacist in the Immune-Mediated Area, Head of the Oncology Section, CHUC)

Lines of research

  1. Germline mutations in the individualization of treatments. Identify genetic alterations that primarily affect the safety and effectiveness of treatments.
  2. Somatic mutations in the individualization of cancer treatments. Identify genetic alterations that affect the effectiveness of treatments.
  3. Monitoring of plasma drug levels. To highlight the clinical value of the therapeutic intervals of drugs by establishing their relationship with their efficacy and safety. 
  4. Adherence to treatments. To study the clinical consequences of a lack of adherence to pharmacological treatment and to analyze the conditions for it.

Funded projects

  • Genetic fingerprinting and individualization of treatment in pediatric onco-hematological patients (PIFIISC22/39). PI: Fernando Gutiérrez Nicolás. Canary Islands Foundation Institute of Health Research of the Canary Islands, FIISC (2023-2024, €18,301.84)
  • Clinical relevance of the UGT1A gene in Sacituzumab-Govitecan treatment for metastatic triple-negative breast cancer. PI: Fernando Gutiérrez Nicolás. Canary Islands Health Research Institute Foundation, FIISC (2023-2025, €18,000)
  • Pharmacokinetics of natalizumab in the treatment of MS. PI: Fernando Gutiérrez Nicolás. Canary Islands Foundation Institute of Health Research of the Canary Islands, FIISC (2023-2025, €8,000)

Publications 2023

  • Cantarelli L, Pestana Grafiña D, Gonzalez Perez A, García Gil S, Gutiérrez Nicolás F, Ramos Santana E, Navarro Dávila MA, Otazo Pérez SM, Calzado Gómez G, Perez Reyes S, Nazco Casariego GJ. Efficacy and Safety of Erenumab, Galcanezumab, and Fremanezumab in the Treatment of Drug-Resistant Chronic Migraine: Experience in Real Clinical Practice. Ann Pharmacother. 2023 Apr;57(4):416-424. DOI: 10.1177/10600280221118402
  • Del Rosario García B, Viña Romero MM, González Rosa V, Alarcón Payer C, Oliva Oliva L, Merino Alonso FJ, Nazco Casariego GJ, Gutiérrez Nicolás F. Incorporation into the ITB, Dr. Gutiérrez F. UI-CHUC Risk factors determining adherence to tyrosine kinase inhibitors in chronic myeloid leukaemia. J Oncol Pharm Pract. 2023 Sep 25:10781552231196130. DOI: 10.1177/10781552231196130. Epub ahead of print
  • Miarons M, Manzaneque Gordón A, Riera P, Gutiérrez Nicolás F; RedDPYD Research Group with the Spanish Society of Hospital Pharmacy (SEFH). Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study. Oncologist. 2023 May;28(5):e304-e308. DOI: 10.1093/oncolo/oyad077
  • Morales-Arráez D, Benítez-Zafra F, Díaz-Flores F, Medina-Alonso MJ, Santiago LG, Pérez-Pérez V, Gutiérrez-Nicolás F, Hernández-Guerra M. A slowdown of hepatitis C diagnosis in high-prevalence groups and with decentralized diagnostic strategies during the COVID-19 pandemic. Spanish Journal of Digestive Diseases. 2023 Apr;115(4):175-180. DOI: 10.17235/reed.2022.8412/2021

Other representative publications from recent years

  • Cantarelli L, Carrillo Palau M, Hernandez Guerra M, Nazco Casariego GJ, Gutierrez Nicolás F. Definition of a therapeutic range for predicting long-term infliximab response in patients with inflammatory bowel disease. Med Clin (Barc). 2023 Feb 10;160(3):107-112. DOI: 10.1016/j.medcli.2022.05.008
  • Del Rosario García B, González García I, Viña Romero MM, González García J, Ramos Díaz R, Mourani Padrón I, Lakhwani Lakhwani S, Nazco Casariego GJ, Gutiérrez Nicolás F. Imatinib plasma levels in patients with chronic myeloid leukaemia under routine clinical practice conditions. J Oncol Pharm Pract. 2021 Oct 18:10781552211052535. DOI: 10.1177/10781552211052535
  • Viña-Romero MM, Ramos-Diaz R, Mourani-Padron I, Gonzalez-Mendez H, Gonzalez-Cruz M, Nazco-Casariego GJ, Merino-Alonso JF, Diaz-Vera J, Gutiérrez-Nicolás F. Extended Stability of Reconstituted Lyophilized Erwinia L-asparaginase in Vials. In Vivo. 2020;34(5):2419-2421. DOI: 10.21873/invivo.12055
  • Viña-Romero MM, Ramos Díaz R, González García J, Nazco-Casariego G, Díaz-Vera J, Gutiérrez-Nicolás F. Extended enzymatic stability of reconstituted lyophilized PEG-asparaginase in vials. J Oncol Pharm Pract. 2021 Jul;27(5):1102-1105. DOI:10.1177/1078155220950001